

CORRIGENDUM

The emerging safety profile of JAK inhibitors in rheumatic disease

*Kevin L. Winthrop**Nature Reviews Rheumatology* 13, 234–243 (2017)

In 'Gastrointestinal perforation' of the 'Adverse effects of JAK inhibitors' section, in the sentence "In patients with RA receiving baricitinib, two cases of gastrointestinal perforations were reported (an incidence of 5 cases per 1,000 patient-years in the development program)" the incidence should have been 0.5 cases per 1,000 patient-years. This error has been corrected in the online version of the article.